Interpretation of HLA single antigen bead assays

Transplantation Reviews

Volumn 27, Issue 4, 2013, Pages 108-111

  Ellis, Thomas M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; EPITOPE; FLUOROCHROME; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN G ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; FLOW CYTOMETRY; FLUORESCENCE; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL HISTORY; REVIEW; SIGNAL NOISE RATIO; SINGLE ANTIGEN BEAD ASSAY; TITRIMETRY;

ANIMALS; ANTIBODIES; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION;

EID: 84884816317     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2013.07.001     Document Type: Review

References (23)

1. Cecka J.M., Kucheryavaya A.Y., Reinsmoen N.L., Leffell M.S. Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011, 11:719-724.
2. Bray R.A., Murphey C., Schaub S. Calculated PRA: a process whose time has come or 'deja vu' all over again?. Am J Transplant 2011, 11:650-651.
3. Cecka J.M. Calculated PRA, (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant 2010, 10:26-29.
4. Wiebe C., Gibson I.W., Blydt-Hansen T.D., et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012, 12:1157-1167.
5. Tambur A.R., Leventhal J.R., Zitzner J.R., Walsh R.C., Friedewald J.J. The DQ barrier: improving organ allocation equity using HLA-DQ information. Transplantation 2013, 95:635-640.
6. Bachelet T., Couzi L., Guidicelli G., et al. Anti-Cw donor-specific alloantibodies can lead to positive flow cytometry crossmatch and irreversible acute antibody-mediated rejection. Am J Transplant 2011, 11:1543-1544.
7. Chen G., Sequeira F., Tyan D.B. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Human Immunol 2011, 72:849-858.
8. Kaneku H., O'Leary J.G., Taniguchi M., Susskind B.M., Terasaki P.I., Klintmalm G.B. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transplant 2012, 18:984-992.
9. Tait B.D., Susal C., Gebel H.M., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation. Transplantation 2013, 95:19-47.
10. Pereira S., Perkins S., Lee J.H., et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant?. Human Immunol 2011, 72:492-498.
11. Cai J., Terasaki P.I., Anderson N., Lachmann N., Schonemann C. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009, 88:226-230.
12. Duquesnoy R.J., Mulder A., Askar M., Fernandez-Vina M., Claas F.H. HLAMatchmaker-based analysis of human monoclonal antibody reactivity demonstrates the importance of an additional contact site for specific recognition of triplet-defined epitopes. Human Immunol 2005, 66:749-761.
13. Kosmoliaptsis V., Bradley J.A., Sharples L.D., et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008, 85:1817-1825.
14. Duquesnoy R.J., Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Human Immunol 2007, 68:12-25.
15. Amico P., Honger G., Mayr M., Steiger J., Hopfer H., Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009, 87:1681-1688.
16. Singh N., Djamali A., Lorentzen D., et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010, 90:1079-1084.
17. Lefaucheur C., Loupy A., Hill G.S., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010, 21:1398-1406.
18. Gloor J.M., Winters J.L., Cornell L.D., et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010, 10:582-589.
19. Ginevri F., Nocera A., Comoli P., et al. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 2012, 12:3355-3362.
20. Maecker H.T., Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry 2006, 69:1037-1042.
21. Reed E.F., Rao P., Zhang Z., et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013, [in press].
22. Guidance for industry. Biomedical method validation. Food and Drug Adminstration, Health and Human Services, 2001. p. 13-9.
23. Mohan S., Palanisamy A., Tsapepas D., et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012, 23:2061-2071. [PubMed PMID: 23160511].